Scarica l'app Stockscreener
14.37
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Assessing Amicus Therapeutics (FOLD) Valuation After Strong Recent Share Price Momentum - simplywall.st
Amicus Therapeutics, Inc. $FOLD Shares Sold by Prosight Management LP - MarketBeat
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) After Strong One Year Share Price Performance - simplywall.st
Amicus Therapeutics stock hits 52-week high at 14.38 USD - Investing.com India
Amicus Therapeutics stock hits 52-week high at 14.38 USD By Investing.com - Investing.com Nigeria
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 12-Month HighTime to Buy? - MarketBeat
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis - Yahoo Finance
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio - Yahoo Finance
Amicus Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus - Yahoo Finance
Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Insider Sell: Bradley Campbell Sells 22,500 Shares of Amicus The - GuruFocus
Amicus Therapeutics (FOLD) CEO Bradley Campbell sells 22,500 shares in open market - Stock Titan
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
FDA’s rare disease toolbox not fully used - bioworld.com
JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is It Too Late To Consider Amicus Therapeutics (FOLD) After The Proposed BioMarin Deal Price? - simplywall.st
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting - TipRanks
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Biotech Sector with a 23.7% Revenue Growth - DirectorsTalk Interviews
Bradley Campbell sells 75,000 FOLD shares under 10b5-1 plan (FOLD) - Stock Titan
Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Primecap Management Co. CA Sells 128,200 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Amicus Therapeutics Experiences Revision in Stock Score Amid Mixed Financial Performance - Markets Mojo
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio - simplywall.st
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Growth in Rare Diseases with Strong Revenue Momentum - DirectorsTalk Interviews
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus - Yahoo Finance
Precision Trading with Amicus Therapeutics Inc. (FOLD) Risk Zones - Stock Traders Daily
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results - The AI Journal
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
Amicus Therapeutics: Q4 Earnings Snapshot - kare11.com
Amicus Therapeutics Q4 Highlights: Revenue Growth Amid Losses - Intellectia AI
Amicus Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives - Sahm
Will Amicus Therapeutics Inc. benefit from sector rotationEarnings Overview Report & Daily Entry Point Alerts - mfd.ru
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - The Manila Times
Decoding Amicus Therapeutics Inc (FOLD): A Strategic SWOT Insigh - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Announces Quarterly Earnings Results - MarketBeat
Amicus Therapeutics (FOLD) Beats Q4 Revenue Expectations - GuruFocus
AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView
Is Amicus Therapeutics Inc.’s ROIC above industry averageWeekly Trading Summary & Intraday High Probability Setup Alerts - mfd.ru
TD Cowen cautious on Amicus Therapeutics (FOLD) despite positive 2025 revenue projections - MSN
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections - Finviz
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):